Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

738.00 -6.50 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
42 43 Next >
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was awarded a government contract valued at up to $326 million on Tuesday. 
Via Benzinga
Exposures COVID-19
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapy 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
18 Analysts Have This to Say About Regeneron Pharmaceuticals
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today
Via Benzinga
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Regeneron's Crucial Eylea HD Approval: A Shield Against Potential Biosimilar Competition?
Friday, the FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema,  
Via Benzinga
Exposures Product Safety
Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed
The Vanguard Value Index Fund ETF (ARCA: VTV) has beaten the Vanguard Growth Index Fund ETF (ARCA: VUG) by 5% during the past month. The momentum shift comes as investors recalibrate their strategies... 
Via Benzinga
Topics ETFs
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder
The FDA approved  Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient  
Via Benzinga
Exposures Product Safety
Why the quality investor may take a look at NASDAQ:REGN.
REGENERON PHARMACEUTICALS (NASDAQ:REGN) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Why This Regeneron Approval 'Could Not Come Soon Enough' As Novartis Looms
The FDA signed off on Regeneron's high-dose Eylea about two months earlier than expected. 
Via Investor's Business Daily
Exposures Product Safety
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
Exposures Product Safety
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Strong Biotech Performers To Watch As Sector Nears Breakout
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming. 
Via MarketBeat
Topics ETFs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica (Nasdaq - SOLO), Computer Task Group, Incorporated (Nasdaq - CTG), Decibel Therapeutics, Inc. (Nasdaq - DBTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales
The company is working on a treatment for stomach diseases ulcerative colitis and Crohn's disease. 
Via Investor's Business Daily
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
The 7 Best Value Stocks to Buy in August
Stop chasing the hot flavors of the week and instead be friendly to your wallet with these ideas for best value stocks to buy. 
Via InvestorPlace
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced two-year (96 weeks) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related  
Via Benzinga
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Top Biotech Stocks Defying the Bear Market
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics
Via Benzinga
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
Decibel Therapeutics Stock Soars on Acquisition Deal - The Details
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has agreed to acquire Decibel Therapeutics Inc (NASDAQ: DBTX) at $4.00 per share with an additional contingent value right of up to $3.50 per share in cash... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback